01:50 PM EST, 11/06/2025 (MT Newswires) -- Evommune ( EVMN ) shares rose 21% to $19.42 in their New York Stock Exchange debut on Thursday after the clinical-stage biotechnology company raised $150 million in an initial public offering.

The offering of 9.4 million Class A shares was priced at $16 apiece. Underwriters have a 30-day option to purchase up to about 1.41 million additional shares.

The IPO is expected to close Friday.

The stock opened at $17.25 on Thursday and reached $20.17.

Price: 19.42, Change: +3.42, Percent Change: +21.34